Literature DB >> 19390479

Antibiotic prophylaxis improves Ureaplasma-associated lung disease in suckling mice.

Scott A Walls1, Lingkun Kong, Hedda A Leeming, Frank X Placencia, Edwina J Popek, Leonard E Weisman.   

Abstract

Ureaplasma infection is associated with increased lung disease in high-risk neonates. Our goal was to determine the impact of antibiotic prophylaxis on Ureaplasma and oxygen-induced lung disease in newborn mice. In animal model development and prophylaxis experiments, pups were randomly assigned to either 0.8 or 0.21 inspired oxygen concentration [fraction of inspired oxygen (FiO2)] from 1 to 14 d of age and either Ureaplasma or 10 B media daily from 1 to 3 d. All pups were observed for growth and survival. Surviving pups had culture and PCR evaluated for blood, bronchoalveolar lavage, and lung, and lung weights, pathology, morphometry, histology, and immunohistochemistry were determined. In prophylaxis experiments, erythromycin, azithromycin, or normal saline was given for the first 3 d, and minimum inhibitory concentration and pharmacokinetics were determined. In model development, 0.8 FiO2 and Ureaplasma infection survival and growth were significantly decreased and lung edema and inflammation were significantly increased. In prophylaxis experiments, we observed significantly improved survival and growth with azithromycin versus normal saline controls, whereas erythromycin was not significantly different from controls, and decreased inflammatory response with azithromycin versus normal saline and erythromycin. In a neonatal mouse model of Ureaplasma and oxygen-induced lung disease, appropriate antibiotic prophylaxis improves survival and morbidity and decreases lung inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390479     DOI: 10.1203/PDR.0b013e3181aabd34

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Authors:  Rose M Viscardi; Ahmed A Othman; Hazem E Hassan; Natalie D Eddington; Elias Abebe; Michael L Terrin; David A Kaufman; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

Review 2.  Ureaplasma species: role in diseases of prematurity.

Authors:  Rose M Viscardi
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

3.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

4.  Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis.

Authors:  Amelia L Sutton; Edward P Acosta; Kajal B Larson; Corenna D Kerstner-Wood; Alan T Tita; Joseph R Biggio
Journal:  Am J Obstet Gynecol       Date:  2015-01-13       Impact factor: 8.661

Review 5.  Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update.

Authors:  Rose Marie Viscardi; Suhas G Kallapur
Journal:  Clin Perinatol       Date:  2015-10-09       Impact factor: 3.430

6.  Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model.

Authors:  Peta L Grigsby; Miles J Novy; Drew W Sadowsky; Terry K Morgan; Mary Long; Ed Acosta; Lynn B Duffy; Ken B Waites
Journal:  Am J Obstet Gynecol       Date:  2012-10-23       Impact factor: 8.661

7.  Role of biofilm formation in Ureaplasma antibiotic susceptibility and development of bronchopulmonary dysplasia in preterm neonates.

Authors:  Katherine Pandelidis; Amanda McCarthy; Kirsty L Chesko; Rose M Viscardi
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

8.  Ureaplasma infections in pre-term infants: Recent information regarding the role of Ureaplasma species as neonatal pathogens.

Authors:  Tae-Jung Sung
Journal:  Korean J Pediatr       Date:  2010-12-31

9.  Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey.

Authors:  Claudia Pansieri; Chiara Pandolfini; Valery Elie; Mark A Turner; Sailesh Kotecha; Evelyne Jacqz-Aigrain; Maurizio Bonati
Journal:  Sci Rep       Date:  2014-02-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.